|
Characteristics
|
Development cohort
|
Validation cohort
|
|---|
|
Patients (n)
|
116
|
67
|
|
Lesions (n)
|
124
|
72
|
|
Age (years)
|
71.27 ± 8.50
|
71.73 ± 8.53
|
|
Prostate volume (mL)
|
61.56 ± 35.14
|
59.26 ± 27.42
|
|
PSA (ng/mL)
|
19.37 ± 20.45
|
22.12 ± 29.70
|
|
PSAD (ng/mL/cm3)
|
0.38 ± 0.44
|
0.43 ± 0.59
|
|
PCa, n (%)
|
71 (57.3)
|
43 (59.7)
|
|
csPCa, n (%)
|
55 (44.4)
|
37 (51.4)
|
|
MRI T-stage (n)
| | |
|
T2/T3/T4
|
63/8/NA
|
34/8/1
|
|
MRI N-stage (n)
| | |
|
N0/N1
|
66/5
|
38/5
|
|
MRI M-stage (n)
| | |
|
M0/M1
|
69/2
|
39/4
|
|
PI-RADS V2 (n)
| | |
|
2/3/4/5
|
27/23/39/35
|
15/10/27/20
|
|
Gleason score, n (%)
| | |
|
3 + 3 = 6
|
16 (12.9)
|
6 (8.3)
|
|
3 + 4 = 7
|
12 (9.7)
|
11 (15.3)
|
|
4 + 3 = 7
|
16 (12.9)
|
12 (16.7)
|
|
4 + 4 = 8
|
18 (14.5)
|
5 (6.9)
|
|
4 + 5 = 9
|
3 (2.4)
|
3 (4.2)
|
|
5 + 4 = 9
|
2 (1.6)
|
4 (5.6)
|
|
5 + 5 = 10
|
4 (3.2)
|
2 (2.8)
|
- PCa prostate cancer, csPCa clinically significant prostate cancer, PSA prostate-specific antigen, PSAD prostate-specific antigen density, NA not available
